AAV with ALB(1.9) promoter driven EGFP
This AAV expresses EGFP driven by a liver ALB(1.9) promoter.
The ALB(1.9) is a synthetic promoter of ~1.9 Kb. It is based on the human Albumin promoter as well as several other regulatory elements. This synthetic promoter gives an extremely high level of long-term, liver-specific transgene expression that is 100-100 fold greater than that of the CMV promoter. For short-term (1-2 weeks post-injection into mouse liver), ALB(1.9) gives comparable expression relative to that of the CMV promoter. However, the expression level of the CMV promoter decreases 100-1000 fold from its peak level within 10-20 weeks of DNA administration whereas the ALB(1.9) promoter sustains its initial high level of expression for over 1 year. Compared to the regular ALB promoter, which is also commonly used for liver-specific transgene expression, the expression level from ALB(1.9) is about 10-100 fold greater.
EGFP is derived from the Aequorea GFP with a Excitation/Emission spectrum around 488nm/507nm. It is the most commonly used imaging probe. Other fluorescent proteins with similar emission spectrums are Emerald, and T-Sapphire.
Ready-to-use AAV expressing EGFP driven by a liver ALB(1.9) promoter. Available in AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAV-DJ and other serotypes.
Related Citations
- Human GDPD3 overexpression promotes liver steatosis by increasing lysophosphatidic acid production and fatty acid uptake. CCC Key, etc, (2020), Journal of Lipid Research
- Bile canaliculi remodeling activates YAP via the actin cytoskeleton during liver regeneration. K Meyer, etc, (2020), Molecular Systems Biology
- Perilipin 5 deletion in hepatocytes remodels lipid metabolism and causes hepatic insulin resistance in mice. SN Keenan, etc, (2019), Diabetes
- The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity. J Bricambert, etc, (2018), Nature Communications